Hansa Biopharma AB (publ)
SSE:HNSA.ST
32.64 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 134.094 | 154.525 | 33.878 | 6.098 | 3.364 | 3.358 | 3.442 | 2.579 | 5.434 | 4.716 | 1.727 | 2.619 | 1.282 | 4.448 | 2.984 | 0.104 |
Cost of Revenue
| 64.828 | 38.477 | 15.425 | 0.997 | 0.866 | 0.916 | 0.221 | 0.217 | 0.658 | 0.245 | 0.318 | -2.487 | 1.715 | 0 | 0 | 0 |
Gross Profit
| 69.266 | 116.048 | 18.453 | 5.101 | 2.498 | 2.442 | 3.221 | 2.362 | 4.776 | 4.471 | 1.409 | 5.106 | -0.432 | 4.448 | 2.984 | 0.104 |
Gross Profit Ratio
| 0.517 | 0.751 | 0.545 | 0.837 | 0.743 | 0.727 | 0.936 | 0.916 | 0.879 | 0.948 | 0.816 | 1.95 | -0.337 | 1 | 1 | 1 |
Reseach & Development Expenses
| 411.325 | 346.244 | 230.764 | 227.191 | 192.949 | 154.558 | 137.06 | 82.85 | 44.262 | 21.742 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 450.492 | 337.861 | 327.269 | 202.987 | 167.31 | 90.387 | 43.723 | 29.703 | 28.241 | 17.422 | 11.256 | 14.139 | 0 | 0 | 0 | 0 |
Selling & Marketing Expenses
| -1.678 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 448.814 | 337.861 | 327.269 | 202.987 | 167.31 | 90.387 | 43.723 | 29.703 | 28.241 | 17.422 | 11.256 | 14.139 | 0 | 0 | 0 | 0 |
Other Expenses
| 0.286 | 8.063 | 0 | 0 | -0.166 | -0.725 | -1.442 | 0.944 | -1.526 | 11.758 | 7.793 | 7.774 | 27.461 | 24.441 | 18.724 | 16.009 |
Operating Expenses
| 860.139 | 692.168 | 558.033 | 430.178 | 360.093 | 244.22 | 179.341 | 113.497 | 70.977 | 29.18 | 19.049 | 21.913 | 27.461 | 24.441 | 18.724 | 16.009 |
Operating Income
| -790.873 | -576.12 | -539.58 | -425.077 | -357.595 | -246.498 | -176.083 | -111.135 | -66.201 | -24.709 | -17.639 | -16.808 | 24.464 | -19.993 | -15.741 | -15.906 |
Operating Income Ratio
| -5.898 | -3.728 | -15.927 | -69.708 | -106.301 | -73.406 | -51.157 | -43.092 | -12.183 | -5.239 | -10.214 | -6.418 | 19.08 | -4.495 | -5.275 | -153.417 |
Total Other Income Expenses Net
| -39.939 | -33.859 | -8.55 | 4.184 | -1.997 | -1.516 | -0.616 | -0.017 | -0.065 | -4.333 | 0.077 | 0.342 | -49.036 | -0.15 | -0.072 | 16.522 |
Income Before Tax
| -830.812 | -609.979 | -548.13 | -420.893 | -359.592 | -248.014 | -176.699 | -111.152 | -66.266 | -29.042 | -17.562 | -16.466 | -24.572 | -20.143 | -15.812 | 0.617 |
Income Before Tax Ratio
| -6.196 | -3.947 | -16.18 | -69.021 | -106.894 | -73.858 | -51.336 | -43.099 | -12.195 | -6.158 | -10.169 | -6.288 | -19.164 | -4.528 | -5.299 | 5.948 |
Income Tax Expense
| 0.908 | 1.155 | 0.152 | -0.04 | 0.417 | -0.04 | -0.039 | -0.023 | 0 | 0.042 | 0.093 | 0.346 | 0 | -1.3 | 0 | 3.175 |
Net Income
| -831.72 | -611.134 | -548.282 | -420.853 | -360.009 | -247.974 | -176.66 | -111.129 | -66.266 | -29.042 | -17.562 | -16.466 | -24.572 | -18.843 | -15.812 | -2.558 |
Net Income Ratio
| -6.203 | -3.955 | -16.184 | -69.015 | -107.018 | -73.846 | -51.325 | -43.09 | -12.195 | -6.158 | -10.169 | -6.288 | -19.164 | -4.236 | -5.299 | -24.675 |
EPS
| -15.83 | -13.6 | -12.33 | -9.98 | -9 | -6.47 | -4.97 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
EPS Diluted
| -15.83 | -13.6 | -12.33 | -9.98 | -9 | -6.47 | -4.96 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
EBITDA
| -780.135 | -549.286 | -538.305 | -414.752 | -352.108 | -244.62 | -172.261 | -107.66 | -65.212 | -23.318 | -17.45 | -16.335 | -27.894 | -19.993 | -15.359 | -15.474 |
EBITDA Ratio
| -5.818 | -3.555 | -15.89 | -68.014 | -104.669 | -72.847 | -50.047 | -41.745 | -12.001 | -4.944 | -10.104 | -6.237 | -21.754 | -4.495 | -5.147 | -149.259 |